Pfizer received approval from the FDA for QuilliChew ER chewable tablets. QuilliChew ER is available in multiple dosage strengths with scored tablet options to individualize dosage. QuilliChew ER is chewable and can be taken with or without food.

QuilliChew ER significantly improved attention and behavior compared to placebo in a clinical trial. The efficacy of QuilliChew ER was evaluated in a double-blind, randomized, placebo-controlled, parallel group laboratory classroom study in 90 children ages 6 to 12 with ADHD. The average of treatment effects across all time points was statistically significantly superior to placebo. The key secondary endpoint demonstrated improvement versus placebo in attention and behavior.